☆ 4.3 Article

The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma

CLINICAL GENITOURINARY CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study

Daniele Raggi et al.

Summary: Patients with metastatic urothelial carcinoma who develop bone metastases and are treated with immunotherapy have a worse prognosis compared to those without bone involvement, highlighting the need for further research to understand the underlying mechanisms.

CLINICAL GENITOURINARY CANCER (2022)

添加到收藏夹

Article Immunology

Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology

Melissa Bersanelli et al.

Summary: The study found that the prognosis of unselected UTUC patients is still unsatisfactory, but the Sonpavde score can be used as a useful tool in treatment decision-making process.

IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy

Husam A. Alqaisi et al.

Summary: This retrospective study suggests that the presence of bone metastasis (BM) in patients with metastatic urothelial cancer (mUC) is associated with worse overall survival (OS), indicating that BM may be an independent negative prognostic factor. Including BM as a stratification factor in future mUC clinical trial designs may be warranted.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

添加到收藏夹

Review Cell Biology

Thyroid Hormones Interaction With Immune Response, Inflammation and Non-thyroidal Illness Syndrome

Roberto De Luca et al.

Summary: The interdependence between thyroid hormones (THs) and the immune system is crucial for immune response and cell proliferation. THs can regulate gene expression and activate cell membrane receptors to achieve biological activity, and they also participate in inflammasome complex modulation. Additionally, in viral infections, the HPT axis is affected, leading to changes in circulating THs levels.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Article Oncology

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)

Marco Maruzzo et al.

Summary: Thyroid hormone impairment, indicated by a low fT3/fT4 ratio, is a strong prognostic factor for patients with metastatic renal cell carcinoma (mRCC) in the first line setting. This factor is independent of other well-established prognostic factors and is associated with both PFS and OS in mRCC patients.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

G. Fornarini et al.

Summary: The study examined the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) in urothelial carcinoma patients treated with immunotherapy. The combination of SII, PD-L1, and LDH was found to stratify overall survival (OS) better than SII plus PD-L1, indicating its potential as a useful prognostic tool for guiding treatment decisions in these patients.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

G. L. Banna et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis

Haoran Liu et al.

DISEASE MARKERS (2020)

添加到收藏夹

Article Oncology

Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial

Giuseppe Pasqualetti et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Urology & Nephrology

Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors

Guru Sonpavde et al.

JOURNAL OF UROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Immunotherapy and urothelial carcinoma: An overview and future prospectives

Francesco Pierantoni et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)

添加到收藏夹

Article Oncology

Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study

Marta Schirripa et al.

CLINICAL COLORECTAL CANCER (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Degree of Peripheral Thyroxin Deiodination, Frailty, and Long-Term Survival in Hospitalized Older Patients

Giuseppe Pasqualetti et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)

添加到收藏夹

Article Oncology

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients

Anna Buda-Nowak et al.

MEDICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J. Bellmunt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study

Thomas Powles et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Hematology

Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma

Rui Gao et al.

BRITISH JOURNAL OF HAEMATOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg et al.

LANCET (2016)

添加到收藏夹

Review Cell Biology

Thyroid Hormones, Oxidative Stress, and Inflammation

Antonio Mancini et al.

MEDIATORS OF INFLAMMATION (2016)

添加到收藏夹

Article Oncology

Can Non-Thyroid Illness Syndrome Predict Mortality in Lung Cancer Patients? A Prospective Cohort Study

Zehra Asuk Yasar et al.

HORMONES & CANCER (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Hormone Therapy is not Indicated in the Majority of Patients with the Sick Euthyroid Syndrome

Alan Farwell

Endocrine Practice (2013)

添加到收藏夹

Article Urology & Nephrology

Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials

Guru Sonpavde et al.

EUROPEAN UROLOGY (2013)

添加到收藏夹

Article Oncology

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

Joaquim Bellmunt et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Review Endocrinology & Metabolism

Mechanisms behind the non-thyroidal illness syndrome: an update

Maria H. Warner et al.

JOURNAL OF ENDOCRINOLOGY (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.